Navigation Links
Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
Date:10/25/2010

utilization, partially offset by patient population growth.

Combined worldwide sales of Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim) increased 4 percent to $1,254 million in the third quarter of 2010 versus $1,210 million for the third quarter of 2009.  Combined sales of Neulasta and NEUPOGEN in the U.S. were $942 million in the third quarter of 2010 versus $897 million in the third quarter of 2009, an increase of 5 percent due primarily to an increase in the average net sales price.  Combined international sales were $312 million in the third quarter of 2010 versus $313 million for the third quarter of 2009.  Excluding the $6 million unfavorable impact of foreign exchange, international product sales increased 2 percent, reflecting continued conversion from NEUPOGEN to Neulasta.  

Sales of Enbrel® (etanercept) decreased 1 percent in the third quarter of 2010 to $914 million versus $924 million for the third quarter of 2009 due to share declines primarily in dermatology, partially offset by a slight increase in the average net sales price. ENBREL continues to maintain a leading position in both the rheumatology and dermatology segments.

Worldwide sales of Sensipar® (cinacalcet) increased 6 percent to $175 million in the third quarter of 2010 versus $165 million during the third quarter of 2009, primarily as a result of increased international demand.

Vectibix® (panitumumab) sales increased 21 percent to $70 million in the third quarter of 2010 versus $58 million for the third quarter of 2009 driven by an increase in demand in the U.S. and internationally.

Nplate® (romiplostim) sales increased 94 percent to $60 million in the third quarter of 2010 versus $31 million for the third quarter of 2009 driven by an increase in demand in the U.S. and internationally.

Prolia™ (denosumab) sales for the quarter were $10 million, reflecting steady progress with physicians, p
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges
2. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
3. Roper Industries Announces Record Third Quarter Results
4. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
5. China Medicine to Announce Third Quarter 2010 Financial Results on November 10, 2010
6. Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results
7. Thoratec Schedules Third Quarter Conference Call, Webcast
8. Essilor - Third-Quarter 2010 Report
9. CVS Caremark Corporation to Hold Third Quarter 2010 Conference Call
10. VirtualScopics Schedules Third Quarter 2010 Earnings Announcement
11. Danaher Reports Record Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 10 Eli Lilly and Company (NYSE: LLY ... the Second Circuit has agreed with Lilly,s position that a ... payor suit, in which unions and insurers who act as ... court also agreed with Lilly that plaintiffs, overpricing claims should ...
... (NYSE Amex: PTN ) announced that it will ... Conference / 12th Annual Healthcare Conference on Tuesday, September 14, ... September 12-15 at the New York Palace Hotel in New ... Chief Executive Officer of Palatin Technologies, will provide an update ...
Cached Medicine Technology:U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... 11 The Campaign for Tobacco-Free Kids applauds U.S. Senator ... the U.S. Food and Drug Administration (FDA) authority to regulate ... marketing and sales to kids. The U.S. Senate approved ... approved similar legislation, and Congress is expected to quickly send ...
... , WASHINGTON, June 11 The Campaign for Tobacco-Free Kids ... today to approve historic legislation that gives the U.S. Food ... the authority to crack down on tobacco marketing and sales ... 79 to 17. The House has approved similar legislation, ...
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Frank Lautenberg ... that gives the U.S. Food and Drug Administration (FDA) authority ... on tobacco marketing and sales to kids. The U.S. ... House has approved similar legislation, and Congress is expected to ...
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Herb ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... JOURNEY , , Follow McCoy,s Trip at http://www.theunbeatentrack.com ... Travis McCoy, lead vocalist & songwriter of Gym Class Heroes ... Senior Vice President, Social Responsibility, MTV Networks International and Executive ... South Africa, the Philippines and India to raise awareness about ...
... statement of CEO Nancy Brown on the Senate passage of ... today by the American Heart Association: , , The ... ensure a healthier future for our children with passage of ... legislation will allow us to protect them from a dirty ...
Cached Medicine News:Health News:Senator Landrieu Votes to Protect America's Kids from Tobacco 2Health News:Senators Gregg and Shaheen Vote to Protect America's Kids From Tobacco 2Health News:Senators Lautenberg and Menendez Vote to Protect America's Kids from Tobacco 2Health News:Senators Kohl and Feingold Vote to Protect America's Kids From Tobacco 2Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 2Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 3Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 4Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 5
Designed to meet the demands of today's laboratories for RO water....
... L/day of Type III Laboratory-grade Water, RiOs ... up to 8000 L/day of Type III ... Complete Purification and Control Unit, RiOs systems ... providing total control of all parameters within ...
... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
... Model U410 is an upright freezer ... our Innova line, but using conventional ... a cost-effective alternative. Similar in size ... 240 2" boxes. Includes five compartments ...
Medicine Products: